<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21598">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781312</url>
  </required_header>
  <id_info>
    <org_study_id>SMR-2712</org_study_id>
    <secondary_id>SMR-2712</secondary_id>
    <nct_id>NCT01781312</nct_id>
  </id_info>
  <brief_title>Probiotics in IgA Nephropathy</brief_title>
  <official_title>Proof-of-concept Study of Efficacy and Safety of Dietary Supplementation With Probiotics in IgAN Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University Hospital</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>Sweden: Swedish Data Inspection Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have shown an increased gastrointestinal reactivity and increased intestinal
      permeability in IgA nephropathy (IgAN). Probiotic supplementation is known to impact the
      gastrointestinal immune system possibly by improvement of both the immunologic and the
      non-immunologic intestinal barrier. Probiotic supplementation should thus theoretically have
      an effect on IgAN. In this study the investigators will study the efficacy and safety of
      Lactobacillus reuteri.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Change in albuminuria</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in renal function</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IgA/IgG immune complexes</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hematuria</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in immunological markers in blood</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IBS (irritable bowel syndrome) symptoms</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>3 months and 5 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>ProTectis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastrus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ProTectis</intervention_name>
    <arm_group_label>ProTectis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gastrus</intervention_name>
    <arm_group_label>Gastrus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Above 18 years

          -  Primary IgAN, verified by biopsy

          -  Albuminuria &gt; 0.75 g/24 h (verified by at least four sample results within a two
             years period prior to inclusion)

          -  Serum creatinine less than 200 umol/L (verified by at least four sample results
             within a two years period prior to inclusion)

          -  Having signed informed consent form

        Exclusion Criteria:

          -  Participation in another clinical intervention trial

          -  Patients with celiac disease

          -  Patients with secondary IgAN

          -  Creatinine clearance below 30 ml/min (mean of 3 measurements)

          -  Introduction of an ACE inhibitor or angiotensin II receptor blocker during the last
             three months prior to inclusion

          -  Patients treated with immunosuppressive or systemic corticosteroid drugs within the
             last twelve months

          -  Patients using probiotic products within the last three months (includes probiotic
             milk products)

          -  Known allergy or intolerance to any of the ingredients in the probiotic product
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bengt Fellström, MD PhD</last_name>
    <email>bengt.fellstrom@medsci.uu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hilde K Smerud, PhD</last_name>
    <email>hilde.smerud@medsci.uu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anders Fernström, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Anders Fernström, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigrid Lundberg, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sigrid Lundberg, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hosptial</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bengt Fellström, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Bengt Fellström, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 29, 2013</lastchanged_date>
  <firstreceived_date>January 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University Hospital</investigator_affiliation>
    <investigator_full_name>Hilde Kloster Smerud</investigator_full_name>
    <investigator_title>Clinical Research Scientist</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
